Description:
GAUCHER DISEASE, TYPE II
GLUCOSIDASE, ACID BETA; GBA
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Lysosomal Storage Diseases |
Class |
Disorders of Lipid Metabolism |
Cell Type
|
Fibroblast
|
Transformant
|
Untransformed
|
Race
|
White
|
Relation to Proband
|
proband
|
Confirmation
|
Molecular characterization after cell line submission to CCR
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
PDL at Freeze |
5.12 |
Passage Frozen |
4 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase, Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
|
MUTATION VERIFICATION |
Tsuji et al (Proc Natl Acad Sci USA 85:2349-2352 1988) reported that DNA extracted from this culture lacked the Asn-370 to Ser mutation in the glucocerebrosidase gene which was found in 75% of type 1 patients. Reiner et al (DNA 7:107-116 1988) employed a human glucocerebrosidase cDNA in a Northern blot analysis to show that mRNA from this type II Gaucher disease patient had the same three RNA species (6 2.6 & 2.2 kb transcripts) as found in normal placenta. Bergman and Grabowski (Am J Hum Genet 44:741-750 1989) analyzed the major processing steps in the maturation of the lysosomal hydrolase acid B-glucosidase in this type II Gaucher disease fibroblast culture. In normal fibroblasts remodeling of N-linked oligosaccharides resulted in the temporal appearance of three molecular-weight forms of acid B-glucosidase. An initial 64-KDa form containing high mannose-type oligosaccharide side chains was processed quantitatively within 24h to a sialylated 69-KDa form. During the subsequent 96h some of the 69-KDa form is processed to 59-KDa. GM01260 fibroblasts revealed no processing of the 64-KDa form of the enzyme. In addition the newly synthesized enzyme disappeared by 24h. No conversion to the normally present 59-KDa form was observed. These results confirm those reported by Beutler and Kuhl (Proc Natl Acad Sci USA 83:7472-7474 1986) which described a very unstable glucocerebrosidase enzyme precursor for type II Gaucher disease fibroblasts. Wigderson et al (Am J Hum Genet 44:365-377 1989) characterized the human glucocerebrosidase gene from Gaucher disease patients. The results obtained with DNA from this cell culture showed the presence of two mutant alleles. One allele contains a C to G transversion at codon 415 which causes substitution of arginine for proline and creates a new HhaI restriction site. The other allele has a T to C transition at codon 444 that causes a substitution of proline for leucine and creates a new NciI restriction site. These results were confirmed by Theophilus et al (Am J Hum Genet 45:212-225 1989). These authors reported that this type II patient was heterozygous for two mutant alleles: the T to C transition in exon 10 (Leu 444 to Pro 444) and the C to G transversion in exon 9 (Pro 415 to Arg 415). The T to C transition had previously been described by Tsuji et al (N Engl J Med 316: 570-575 1987). |
|
glucosylceramidase |
According to the submitter, biochemical test results for this subject showed decreased enzyme activity. EC Number: 3.2.1.45; 3% activity. |
|
Gene |
GBA |
Chromosomal Location |
1q21 |
Allelic Variant 1 |
606463.0001; GAUCHER DISEASE, NEURONOPATHIC |
Identified Mutation |
LEU483PRO (LEU444PRO), 1448T>C; The leu444-to-pro (L444P) substitution in exon 10 of the GBA gene has been reported as resulting from a 1448T-C transition (Zimran et al., 1989) and from a 6433T-C transition (Latham et al., 1990), depending upon the reference sequence cited. This mutation has alternatively been referred to as LEU483PRO (Saranjam et al., 2013). |
|
Gene |
GBA |
Chromosomal Location |
1q21 |
Allelic Variant 2 |
606463.0002; GAUCHER DISEASE, NEURONOPATHIC |
Identified Mutation |
PRO415ARG, 5976C>G; Wigderson et al. [Am J Hum Genet 44: 365 (1989)] characterized mutations in the human glucocerebrosidase gene in 9 patients with Gaucher disease: 5 with type I, 3 with type II, and 1 with type III disease. Two mutant alleles were described; one was the T-to-C transition resulting in substitution of proline for leucine at position 444 (230800.0001), and the other was a C-to-G transversion resulting in a substitution of arginine for proline at position 415. One type II patient was heterozygous for both mutations (GM01260). The substitution at position 444, which creates a new NciI restriction site, was observed in 3 of the patients with type I disease and in the patient with type III disease. One additional patient with type II disease was homozygous for the leu444-to-pro mutation. |
Remarks |
Splenomegaly; opisthotonos: expired at age 1; 3% of control fibro glucocerebrosidase activity; donor subject is a compound heterozygote: one allele has a T>C transition at nucleotide 1448 in exon 10 of the GBA gene (1448T>C) resulting in the substitution of proline for leucine at codon 444 [Leu444Pro (L444P)]; the second allele has a C>G transversion at nucleotide 1361 in exon 9 (1361C>G) resulting in the substitution of arginine for proline at codon 415 [Pro415Arg (P415R)] [codons are numbered from the first codon of the mature protein; the cDNA is numbered from the first initiating AUG] |
Yañez MJ, Campos F, Marín T, Klein AD, Futerman AH, Alvarez AR, Zanlungo S, c-Abl activates RIPK3 signaling in Gaucher disease Biochimica et biophysica acta Molecular basis of disease1867:166089 2020 |
PubMed ID: 33549745 |
|
Sun Y, Liou B, Chu Z, Fannin V, Blackwood R, Peng Y, Grabowski GA, Davis HW, Qi X, Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease EBioMedicine1867:102735 2019 |
PubMed ID: 32279952 |
|
Fog CK, Zago P, Malini E, Solanko LM, Peruzzo P, Bornaes C, Magnoni R, Mehmedbasic A, Petersen NHT, Bembi B, Aerts JFMG, Dardis A, Kirkegaard T, The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase EBioMedicine38:142-153 2018 |
PubMed ID: 30497978 |
|
Sasagasako N, Kobayashi T, Yamaguchi Y, Shinnoh N, Goto I, Glucosylceramide and glucosylsphingosine metabolism in cultured fibroblasts deficient in acid beta-glucosidase activity. J Biochem (Tokyo)115:113-9 1994 |
PubMed ID: 8188616 |
|
Fink JK, Correll PH, Perry LK, Brady RO, Karlsson S, Correction of glucocerebrosidase deficiency after retroviral-mediated gene transfer into hematopoietic progenitor cells from patients with Gaucher disease. Proc Natl Acad Sci U S A87:2334-8 1990 |
PubMed ID: 2315324 |
|
Firon N, Eyal N, Kolodny EH, Horowitz M, Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. Am J Hum Genet46:527-32 1990 |
PubMed ID: 2309702 |
|
Zimran A, Gelbart T, Beutler E, Linkage of the PvuII polymorphism with the common Jewish mutation for Gaucher disease. Am J Hum Genet46:902-5 1990 |
PubMed ID: 1971142 |
|
Bergmann JE, Grabowski GA, Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. Am J Hum Genet44:741-50 1989 |
PubMed ID: 2495719 |
|
Theophilus B, Latham T, Grabowski GA, Smith FI, Gaucher disease: molecular heterogeneity and phenotype-genotype correlations. Am J Hum Genet45:212-25 1989 |
PubMed ID: 2502917 |
|
Wigderson M, Firon N, Horowitz Z, Wilder S, Frishberg Y, Reiner O, Horowitz M, Characterization of mutations in Gaucher patients by cDNA cloning. Am J Hum Genet44:365-77 1989 |
PubMed ID: 2464926 |
|
Reiner O, Wigderson M, Horowitz M, Structural analysis of the human glucocerebrosidase genes. DNA7:107-16 1988 |
PubMed ID: 3359914 |
|
Tsuji S, Martin BM, Barranger JA, Stubblefield BK, LaMarca ME, Ginns EI, Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals [published erratum appears in Proc Natl Acad Sci U S A 1988 Aug;85(15):5708] Proc Natl Acad Sci U S A85:2349-52 1988 |
PubMed ID: 3353383 |
|
Reiner O, Wilder S, Givol D, Horowitz M, Efficient in vitro and in vivo expression of human glucocerebrosidase cDNA. DNA6:101-8 1987 |
PubMed ID: 2438102 |
|
Tsuji S, Choudary PV, Martin BM, Stubblefield BK, Mayor JA, Barranger JA, Ginns EI, A mutation in the human glucocerebrosidase gene in neuronopathic Gaucher's disease. N Engl J Med316:570-5 1987 |
PubMed ID: 2880291 |
|
Beutler E, Kuhl W, Glucocerebrosidase processing in normal fibroblasts and in fibroblasts from patients with type I, type II, and type III Gaucher disease. Proc Natl Acad Sci U S A83:7472-4 1986 |
PubMed ID: 3463977 |
|
Pentchev PG, Comly ME, Kruth HS, Patel S, Proestel M, Weintroub H, The cholesterol storage disorder of the mutant BALB/c mouse. A primary genetic lesion closely linked to defective esterification of exogenously derived cholesterol and its relationship to human type C Niemann-Pick disease. J Biol Chem261:2772-7 1986 |
PubMed ID: 3949747 |
|
Ginns EI, Choudary PV, Tsuji S, Martin B, Stubblefield B, Sawyer J, Hozier J, Barranger JA, Gene mapping and leader polypeptide sequence of human glucocerebrosidase: implications for Gaucher disease. Proc Natl Acad Sci U S A82:7101-5 1985 |
PubMed ID: 3863141 |
|
Grabowski GA, Dinur T, Osiecki KM, Kruse JR, Legler G, Gatt S, Gaucher disease types 1, 2, and 3: differential mutations of the acid beta-glucosidase active site identified with conduritol B epoxide derivatives and sphingosine. Am J Hum Genet37:499-510 1985 |
PubMed ID: 4003396 |
|
Grabowski GA, Goldblatt J, Dinur T, Kruse J, Svennerholm L, Gatt S, Desnick RJ, Genetic heterogeneity in Gaucher disease: physicokinetic and immunologic studies of the residual enzyme in cultured fibroblasts from non-neuronopathic and neuronopathic patients. Am J Med Genet21:529-49 1985 |
PubMed ID: 3927728 |
|
Beutler E, Kuhl W, Sorge J, Cross-reacting material in Gaucher disease fibroblasts. Proc Natl Acad Sci U S A81:6506-10 1984 |
PubMed ID: 6593712 |
|
Michels VV, Berseth CL, O'Brien JF, Dewald G, Duplication of part of chromosome 1q: clinical report and review of literature. Am J Med Genet18:125-34 1984 |
PubMed ID: 6430083 |
|
Silverstein E, Friedland J, Angiotensin converting enzyme in cultured fibroblasts in Gaucher and Niemann-Pick diseases. Proc Soc Exp Biol Med170:251-3 1982 |
PubMed ID: 6283559 |
dbSNP |
dbSNP ID: 10394 |
Gene Cards |
GBA |
Gene Ontology |
GO:0004348 glucosylceramidase activity |
|
GO:0005764 lysosome |
|
GO:0005975 carbohydrate metabolism |
|
GO:0006665 sphingolipid metabolism |
|
GO:0007040 lysosome organization and biogenesis |
|
GO:0016020 membrane |
|
GO:0016798 hydrolase activity, acting on glycosyl bonds |
NCBI Gene |
Gene ID:2629 |
NCBI GTR |
230900 GAUCHER DISEASE, TYPE II; GD2 |
|
606463 GLUCOSIDASE, BETA, ACID; GBA |
OMIM |
230900 GAUCHER DISEASE, TYPE II; GD2 |
|
606463 GLUCOSIDASE, BETA, ACID; GBA |
Omim Description |
GAUCHER DISEASE, ACUTE NEURONOPATHIC TYPE |
|
GAUCHER DISEASE, INFANTILE CEREBRAL |
|
GAUCHER DISEASE, TYPE II |
|
GD II |
Passage Frozen |
4 |
Split Ratio |
1:3 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Supplement |
- |
|
|